润都股份: 2025年半年度报告摘要

Core Viewpoint - Zhuhai Rundu Pharmaceutical Co., Ltd. reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance and financial health [2][3]. Financial Performance - The company's operating revenue for the reporting period was approximately 548.07 million yuan, a decrease of 8.22% compared to the same period last year [2]. - The net profit attributable to shareholders was a loss of approximately 36.19 million yuan, representing a decline of 195.75% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was a loss of approximately 44.85 million yuan, down 242.47% from the previous year [2]. - The net cash flow from operating activities was approximately 9.45 million yuan, a decrease of 88.54% compared to the same period last year [2]. - Basic and diluted earnings per share were both -0.11 yuan, a drop of 200% year-on-year [2]. - The weighted average return on equity was -3.22%, down 6.40% from the previous year [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 2.12 billion yuan, a decrease of 3.35% from the end of the previous year [3]. - The net assets attributable to shareholders were approximately 1.07 billion yuan, down 7.50% from the previous year-end [3]. Shareholder Information - The top two shareholders, Li Xi and Chen Xinmin, each hold 30.12% of the shares, collectively controlling 60.24% of the company [3][4]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4]. Important Events - The company clarified that it has not engaged in the production or sale of toxic or harmful food products, despite allegations against another pharmaceutical company [4]. - The company is actively monitoring the situation and will fulfill its disclosure obligations as required by law and the Shenzhen Stock Exchange [4].